JOHNSON & JOHNSON
Follow13F filer, CIK 200406, NEW BRUNSWICK, NJ
JOHNSON & JOHNSON reported $761,691,304 across 15 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-10-26. Its ten largest share positions make up 98.81% of the portfolio.
Accepted , ingested 13F-HR 0000904454-26-000541
- Period
- 2026-09-30
- Reported value
- $762M
- Holdings
- 15
- Top 10 weight
- 98.81%
- New
- 0
- Sold out
- 0
Part of the filer group JOHNSON & JOHNSON
How groups are builtStakes and trades reported after 2026-09-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- TRXB TREX BIO INC: 13G 1,475,302 shares, 5.3% of the class, 13G filed 2026-10-15, 0000904454-26-000517Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| CBRSadded | +75,063 | $13.3M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
None.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0000904454-26-000541, largest first. % of portfolio is the value over $761,691,304, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| PTGXPROTAGONIST THERAPEUTICS INC | 2,449,183 | $345M | 45.3% | 0 | Timeline | ||
| NBTXNANOBIOTIX | 5,623,816 | $175M | 23.01% | 0 | Timeline | ||
| MGTXMEIRAGTX HLDGS PLC | 6,641,064 | $73.1M | 9.59% | 0 | Timeline | ||
| RAPPRAPPORT THERAPEUTICS INC | 1,784,517 | $60M | 7.87% | 0 | Timeline | ||
| CTNMCONTINEUM THERAPEUTICS INC | 1,979,173 | $26.6M | 3.49% | 0 | 2026-11-03, 13G/A: 1,979,173 shares, 5.6% of the class, 13G/A filed 2026-11-06 | Timeline | |
| CBRSCEREBRAS SYSTEMS INC | 128,649 | $22.9M | 3% | +75,063 | Timeline | ||
| XNCRXENCOR INC | 748,062 | $18.7M | 2.45% | 0 | Timeline | ||
| LEGNLEGEND BIOTECH CORP | 814,586 | $16.2M | 2.13% | 0 | Timeline | ||
| FATEFATE THERAPEUTICS INC | 3,379,064 | $8.01M | 1.05% | 0 | Timeline | ||
| CVRXCVRX INC | 4,024,861 | $7.04M | 0.92% | 0 | Timeline | ||
| PRCTPROCEPT BIOROBOTICS CORP | 357,939 | $6.52M | 0.86% | 0 | Timeline | ||
| NMRANEUMORA THERAPEUTICS INC. | 1,849,445 | $1.1M | 0.14% | 0 | Timeline | ||
| VORVOR BIOPHARMA INC | 53,732 | $1.03M | 0.13% | 0 | Timeline | ||
| LABSTANDARD BIOTOOLS INC | 311,967 | $231K | 0.03% | 0 | Timeline | ||
| ACETADICET BIO INC | 22,779 | $163K | 0.02% | 0 | Timeline |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000904454-26-000541 | base | 2026-10-26 |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000904454-26-000541 | Quarter ended 2026-09-30 | 2026-10-26 | ||
| 13F-HR 0000904454-26-000435 | Quarter ended 2026-06-30 | 2026-08-06 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-26-000280 | Quarter ended 2026-03-31 | 2026-05-13 | acceptance time not in the bulk data set | |
| 13F-HR/A 0000904454-26-000192 | Quarter ended 2025-12-31 | 2026-03-18 | acceptance time not in the bulk data set | |
| 13F-HR/A 0000904454-26-000190 | Quarter ended 2025-09-30 | 2026-03-18 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-26-000111 | Quarter ended 2025-12-31 | 2026-02-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-25-000587 | Quarter ended 2025-09-30 | 2025-11-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-25-000367 | Quarter ended 2025-06-30 | 2025-07-22 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-25-000238 | Quarter ended 2025-03-31 | 2025-05-07 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-25-000124 | Quarter ended 2024-12-31 | 2025-02-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-24-000604 | Quarter ended 2024-09-30 | 2024-11-13 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-24-000451 | Quarter ended 2024-06-30 | 2024-08-09 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-24-000285 | Quarter ended 2024-03-31 | 2024-05-10 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-24-000151 | Quarter ended 2023-12-31 | 2024-02-14 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-23-000600 | Quarter ended 2023-09-30 | 2023-11-09 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-23-000459 | Quarter ended 2023-06-30 | 2023-08-02 | acceptance time not in the bulk data set | |
| 13F-HR 0000904454-23-000307 | Quarter ended 2023-03-31 | 2023-05-11 | acceptance time not in the bulk data set | |
| 13F-HR 0001567619-23-002139 | Quarter ended 2022-12-31 | 2023-02-09 | acceptance time not in the bulk data set | |
| 13F-HR 0001567619-22-019556 | Quarter ended 2022-09-30 | 2022-11-10 | acceptance time not in the bulk data set | |
| 13F-HR 0001567619-22-015421 | Quarter ended 2022-06-30 | 2022-08-10 | acceptance time not in the bulk data set | |
| 13F-HR 0001567619-22-009807 | Quarter ended 2022-03-31 | 2022-05-09 | acceptance time not in the bulk data set | |
| 13F-HR 0001567619-22-004279 | Quarter ended 2021-12-31 | 2022-02-14 | acceptance time not in the bulk data set | |
| 13F-HR/A 0001567619-21-020557 | Quarter ended 2021-09-30 | 2021-11-16 | acceptance time not in the bulk data set | |
| 13F-HR 0001567619-21-020090 | Quarter ended 2021-09-30 | 2021-11-12 | acceptance time not in the bulk data set | |
| 13F-NT 0001567619-21-014325 | Quarter ended 2021-06-30 | 2021-08-03 | acceptance time not in the bulk data set | |
| 13F-NT 0001567619-21-009229 | Quarter ended 2021-03-31 | 2021-05-07 | acceptance time not in the bulk data set | |
| 13F-NT 0001567619-21-002492 | Quarter ended 2020-12-31 | 2021-02-09 | acceptance time not in the bulk data set | |
| 13F-NT 0001567619-20-018620 | Quarter ended 2020-09-30 | 2020-11-03 | acceptance time not in the bulk data set | |
| 13F-NT 0001567619-20-014845 | Quarter ended 2020-06-30 | 2020-08-12 | acceptance time not in the bulk data set | |
| 13F-NT 0001567619-20-009798 | Quarter ended 2020-03-31 | 2020-05-13 | acceptance time not in the bulk data set | |
| 13F-NT 0001567619-20-003767 | Quarter ended 2019-12-31 | 2020-02-14 | acceptance time not in the bulk data set |